PPT-Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Uses vs. Usual Care

Prepared for Agency for Healthcare Research and Quality AHRQ wwwahrqgov Introduction to recombinant activated factor VII rFVIIa Process for developing the comparative effectiveness review CER. The SMART way. FACTOR-LABEL. (aka DIMENSIONAL ANALYSIS). We convert all the time.. When the values are familiar, it is easy.. When the problem is short it is simple.. But in . chem. , you will need to solve problems that are neither familiar nor short!. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. . JAMA 2002;288:2998-3007. ALLHAT- LLT. 10,355 patients with moderate hypercholesterolemia . All patients enrolled in the ALLHAT antihypertensive trial. Analysis . (aka . Factor-Label). . This technique involves the use of conversion factors and writing all measurements with both numerical values and the unit of measurement. A conversion factor is where you have the same amount (entity) represented by two different units of measurement with their corresponding numerical values. Prepared for:. Agency for Healthcare Research and Quality (AHRQ). www.ahrq.gov. Introduction to recombinant activated factor VII (rFVIIa). Process for developing the comparative effectiveness review (CER). Adults who went without care because of cost in past year. Adults without a usual source of care. Exhibit 1. Source:  2014 Behavioral Risk Factor Surveillance System (BRFSS). Percent:. Preventable Death Rate for Blacks Is Double the Rate for Whites. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. . JAMA 2002;288:2998-3007. ALLHAT- LLT. 10,355 patients with moderate hypercholesterolemia . All patients enrolled in the ALLHAT antihypertensive trial. of cognitive behavioural therapy. for treatment resistant depression in primary care. . A follow-up of the . CoBalT. trial. Chris Williams on behalf of the . CoBalt. Trial . Team . led . by Nicola Wiles, Bristol. 2012. Michael Recht, MD, PhD. Director, The Hemophilia Center. Oregon Health & Science University. Disclosures. Research funding directly to OHSU from. NovoNordisk. Baxter. Biogen. Idec. Pfizer. Proc.Natl.Acad.Sci.USA86(1989)1383includingthreeion-exchangechromatographystepsandimmunoadsorptiononaSepharose4Bcolumn(Pharmacia)towhichamonoclonalantibody(mAb)againsthumanplasmafactorVIIwascoupled.On Research into practice. Perspectives from a Former “PCORIAN”. Kara Odom Walker, MD, MPH, MSHS, FAAFP. Cabinet Secretary, Department of Health and Social Services. May 15, 2017. An independent research institute authorized by Congress in 2010 and governed by a 21-member Board of Governors representing the entire health care community. Jodi B Segal, MD, MPH. Professor of Medicine, Epidemiology, Health Policy and Management. Johns Hopkins University School of Medicine and. Bloomberg School of Public Health. Doctor, should I be taking aspirin to prevent a heart attack? I know that I have some worrisome risk factors…. NOTES: * In past 12 months. Respondents who said usual source of care was the emergency room were included among those not having a usual source of care. All differences between uninsured and insurance groups are statistically significant (p<0.05).. Prepared for:. Agency for Healthcare Research and Quality (AHRQ). www.ahrq.gov. This presentation will:. Show how to choose concurrent, active comparators from the same source population (or justify the use of no-treatment comparisons/ historical comparators/different data sources). Introduction. Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence of OHCA is estimated at 110 individuals per 100,000 . The overall survival rate is 10.8%. The American Heart Association (AHA) guidelines recommends angiography for patients who have ST elevation in electrocardiogram followed by proper treatments. In patients without ST elevation, other general test and observations would be conducted before further interventions. Some evidence suggests that angiography and immediate percutaneous intervention for OHCA patients could result in better healthcare outcomes regardless of the presence of ST elevation in electrocardiogram. The goal of this study is to investigate whether immediate angiography and PCI are cost-effective compared to the standard of care.  It is important to state the time duration..